Immunovant (IMVT) Long-Term Investments (2019)
Immunovant (IMVT) reported Long-Term Investments of $116.0 million for Q3 2019, up 0.59% quarter-over-quarter from $115.3 million in Q2 2019.
Immunovant (IMVT) Long-Term Investments (2019) Analysis & Trends
Immunovant has reported Long-Term Investments for 1 years, with the latest figure at $116.0 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 116.02 Mn |
| Jun 30, 2019 | 115.34 Mn |